Startup SilaGene Aims to Develop U1 Adaptor Gene-Silencing Tech as Therapeutic Platform

At this point, however, SilaGene remains a two-man operation in need of financing, and funding from the National Institutes of Health will be vital for the company to generate key in vivo data.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.